Truqap recommended for EU breast cancer approval | Company Announcement
Investegate announcements from Truqap recommended for EU breast cancer approval
Source: investegate.co.uk
Therapy Alone News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Therapy Alone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Therapy Alone Today - Breaking & Trending Today
Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or ...
Source: pharmiweb.com
AstraZeneca : Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Form 6-K -April 02, 2024 at 07:58 am EDT
A9023i FORM 6-K SECURITIES AND EXCHANGE COMMISSION ...
Source: marketscreener.com
AstraZeneca : Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer -March 27, 2024 at 03:09 am EDT
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations Approval based on CAPItello-291 results which showed...
Source: marketscreener.com
AstraZeneca's Truqap approved in the US for HR-positive breast cancer
AstraZeneca's Truqap approved in the US for HR-positive breast cancer
Source: directorstalkinterviews.com